(Q42225157)

19 October 2017

title

Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections (English)

1 reference

19 October 2017

1 reference

3

1 reference

19 October 2017

6

1 reference

19 October 2017

Felisart J

1

1 reference

19 October 2017

Rimola A

2

1 reference

19 October 2017

Perez-Ayuso RM

4

1 reference

19 October 2017

Quintero E

5

1 reference

19 October 2017

Rodes J

7

1 reference

19 October 2017

language of work or name

English

0 references

publication date

1 May 1985

1 reference

19 October 2017

1 reference

19 October 2017

volume

5

1 reference

19 October 2017

issue

3

1 reference

19 October 2017

page(s)

457-462

1 reference

Empiric Therapy for Cancer Patients: Comparative Study of Ticarcillin-Tobramycin, Ticarcillin-Cephalothin, and Cephalothin-Tobramycin

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

The evaluation of efficacy and safety of cefotaxime: a review of 2500 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

Cefotaxime therapy of serious bacterial infection in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

Gentamicin therapy in renal failure: a nomogram for dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

21 January 2018

Tobramycin: an overview

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

Laboratory and clinical evaluation of tobramycin, a new aminoglycoside antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

Clinical evaluation of tobramycin in respiratory and systemic infections in immunodepressed and normal patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

Spontaneous Bacterial Peritonitis in Cirrhosis: Endemic or Epidemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Reticuloendothelial System Phagocytic Activity in Cirrhosis and Its Relation to Bacterial Infections and Prognosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Antibiotic combination-associated nephrotoxicity in granulocytopenic patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Cefotaxime A review of its Antibacterial Activity, Pharmacological Properties and Therapeutic Use

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Antibacterial activity of cefotaxime and other newer cephalosporins (in vitro and in vivo)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Antibacterial activity of cefotaxime

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Cefotaxime in serious infections—a clinical and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Cefotaxime: pharmacokinetics and in vitro antibacterial activity of serum and urine in normal human volunteers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Cefotaxime concentrations in ascites

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Sensitivity testing and synergy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

The nephrotoxicity of antimicrobial agents (second of three parts).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Rapid intravenous injection of tobramycin: suggested dosage schedule and concentrations in serum

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Blood polymorphonuclear dysfunction in patients with alcoholic cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Serum complement in chronic liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

In vitro and in vivo studies of cellular immunity in alcoholic cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Cefotaxime in urinary tract infections--comparative clinical studies with gentamicin and with cefoxitin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840050319

7 January 2021

Identifiers

DOI

10.1002/HEP.1840050319

1 reference

19 October 2017

1 reference